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few CEDs (8%) for which there were SEP (e.g. monitoring of HbA1c for antidiabetics 
in Italy). ConClusions: Although SEP are considered as not reliable from payers’ 
perspective to fund newly approved products, they have become widely acceptable 
for defining success criteria in P4P. This highlights the limitation of P4P, and more 
research would be needed to assess the actual predictive value of such endpoints. 
On the opposite, CED appears to be an appropriate tool to address payers’ uncer-
tainty as they rely on HEP for decision making.
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objeCtives: Decision makers in middle income countries are using pharma-
coeconomics studies (PEs) and health technology assessments (HTAs) in pricing 
and reimbursement decisions. However, whilst many of these jurisdictions have 
local submission guidelines and local expertise, the studies themselves often use 
models developed elsewhere and elements of data from countries other than the 
jurisdiction concerned. The objectives of this study were to assess the challenges 
faced by decision makers in transferring pharmacoeconomic data and analyses 
from other jurisdictions. Methods: We conducted an interview survey of repre-
sentatives of decision making bodies from jurisdictions in Asia, Central and Eastern 
Europe, and Latin America that had at least one year’s experience of using PEs and 
HTAs. Results: Representatives of the relevant organizations in 12 countries were 
interviewed. All 12 jurisdictions had developed official guidelines for the conduct of 
HTAs or PEs. All but one of the organizations evaluated studies submitted to them, 
but 9 also conducted studies and 7 commissioned them. Nine of the organizations 
stated that, in evaluating HTAs or PEs submitted to them, they had consulted a 
study performed in a different jurisdiction. Data on relevant treatment effect was 
generally considered more transferable than those on prices/unit costs. Views on 
the transferability of epidemiological data, data on resource use and health state 
preference values were more mixed. Eight of the respondents stated that analyses 
submitted to them had used models developed in other jurisdictions. Four of the 
organizations had a policy requiring models to be adapted to reflect local circum-
stances. ConClusions: Decision makers in middle income countries were facing 
several challenges in transferring data or studies, mainly due to differences in cur-
rent standard of care, practice patterns or GDP between the developed countries 
where the majority of the studies are conducted and their own jurisdiction.
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bACkgRound: GWAS can identify targets of marketed drugs that are strongly asso-
ciated with disease(s) different from approved indication, providing opportunities 
to substantially shorten the drug development process by repositioning the drug as 
treatment for the newly identified disease, potentially yielding substantial socio-
economic benefits. objeCtives: To estimate economic benefits of repositioning 
three drugs to GWAS-identified diseases Methods: GWAS were used to identify 
denosumab (currently for osteoporosis) as possible treatment for Crohn’s disease, 
melatonin (circadian adjustment) for diabetes, and niacin (lipid-lowering) for aortic 
stenosis (AS). Economic models were constructed for the three illnesses--using data 
from Canadian registries, claims databases and clinical trials--comparing current 
management of the target illness with use of the repositioned drug. Costs (2013 CAD) 
were obtained from Medicare, Ontario Case Costing Project and price lists. Analyses 
covered each province and Canada. Results: In all three cases, the repositioned 
product was dominant over current treatment mix, even at relatively low levels of 
uptake (> 5%). With 50% uptake, in Crohn’s, denosumab would provide substan-
tial reductions in side-effects and savings of $1,619/pt, resulting in $161 million in 
annual savings across Canada; in diabetes, melatonin would save $205/pt annu-
ally, or more than $365 million for Canada, assuming equal efficacy; in AS, niacin 
would save $4.5 million in Quebec alone, largely by averting valve replacement 
surgery, providing additional benefits via reduced associated morbidity and mortal-
ity. Extensive sensitivity analyses showed these results to remain directionally the 
same except at extremely low rates of uptake or with significant increases in the 
price of the repositioned product. ConClusions: Using GWAS data to reposition 
existing drugs to other diseases offers sizeable reductions in the cost and time of 
drug development and would provide considerable economic benefits to the health 
care system. Additional efforts should be made to pursue this attractive path to 
effective “novel” treatments
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objeCtives: The study aims to assess general public awareness towards issues 
related to medication safety in Quetta City, Pakistan. Methods: A cross-sectional 
copayment amount [41.2% with an increase in generic copayment amount; 74.5% 
with an increased in preferred brand copayment amount; 68.5% with an increase 
in non-preferred brand copayment amount]. ConClusions: 12% of continuously 
enroll beneficiaries experienced benefit design changes that could impact prescrip-
tion utlization and adherence measures. Most of them experienced an increased 
in copayment amount, especially for brand name formulary drugs. Benefit design 
should be incorporated into prescription utilization and adherence studies to more 
accurately estimate these measures.
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objeCtives: Several jurisdictions assess the relative clinical effectiveness of new 
therapeutic agents compared to existing products and assign rankings of thera-
peutic improvement. These rankings influence and sometimes determine the 
potential pricing of the product in the respective jurisdiction. This study sought 
to compare the level of therapeutic improvement assessments in three jurisdic-
tions and discuss the parameters leading to any differences observed in level of 
therapeutic improvement rankings. Methods: Efforts were taken to standardize 
the level of therapeutic ranking systems of Canada, France and Germany to have 
comparable levels of therapeutic improvement. We identified 128 unique substances 
reviewed by Canada’s Patented Medicines Price Review Board (PMPRB) between 
2011 and 2013 for which level of therapeutic improvement rankings were assigned. 
Of these, 18 were also reviewed by the Haute-Autorité de Santé (HAS) in France and 
the Federal Joint Committee (GB-A) in Germany. The level of therapeutic improve-
ment rankings were observed in each jurisdiction to assess concurrence among the 
organizations. Results: Preliminary results indicated that there was concurrence 
in the level of therapeutic improvement rankings across the jurisdictions with most 
products receiving low levels of therapeutic improvement (n= 13). ConClusions: 
Overall, concurrence was observed among the agencies’ level of therapeutic 
improvement rankings for the 18 drugs commonly evaluated. Elements such as a 
review’s timing and order, the primary indication and relevant comparators identi-
fied in the therapeutic area by each jurisdiction are important to understand dis-
crepancies in level of therapeutic improvement suggested. Discussion surrounding 
limitations of standardization is necessary to inform results.
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objeCtives: The adoption of elective biomarker tests within US health plans has 
been slow. Without standardized guidelines, payers vary in their coverage policies of 
elective biomarker diagnostics. The aim of this study was to identify factors, includ-
ing the positive predictive value (PPV) of a test, that influence current coverage and 
reimbursement practices of elective biomarker tests amongst US payers. Methods: 
Independent assessments were conducted with two groups of US payers comprised 
of both medical and pharmacy directors from national and regional health plans. 
In October 2013, a focus group of 44 US payers used 7-point Likert scales to evaluate 
hypothetical scenarios involving varying PPVs. In December 2013, 60 US payers were 
surveyed using 7-point Likert scales to categorize factors that influence the coverage 
of elective biomarker diagnostics within their health plans. Elective biomarkers were 
defined as diagnostic tests that are not required as part of the FDA-approved labe-
ling, but may be used in conjunction since evidence demonstrates that test results 
may determine treatment choices and/or outcomes. Chi-squared analyses are in 
progress to observe differences in responses between the two independent payer 
groups, medical and pharmacy directors, as well as national and regional health 
plans. Results: Based on focus group results, 6 (13.6%), 13 (29.5%), 31 (70.5%), and 
40 (90.1%) US payers were more likely to cover biomarker tests as PPV increased from 
20%, 40%, 60% and 80%, respectively. 52 (86.6%) surveyed payers rated the ability to 
predict the effectiveness of a particular therapy, and 42 (70.0%) rated the ability to 
reduce the frequency of other clinical tests as the main factors influencing coverage 
decisions. ConClusions: In lieu of standardized guidelines, this research indicates 
that the more accurate and effective the biomarker test is at determining treatment 
choices and/or outcomes, the more likely it will be covered by US health plans.
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objeCtives: Payers are strongly reluctant to value surrogate endpoints (SEP) as 
they carry substantial uncertainty on the final endpoint. However, it seems that SEP 
are common in payment for performance (P4P) agreements. The objective of this 
project was to Identify the proportion of SEP used in P4P and coverage with evidence 
development (CED). Methods: Market access agreements (MAA) were identified 
from literature review, completed agencies websites, and experts input. P4P and 
CED were selected. Performance endpoints were classified as SEP or hard endpoint 
(HEP). Results: 149 MAA were identified in 13 countries (France, UK, Italy, Sweden, 
Lithuania, Serbia, Slovenia, Germany, Denmark, Portugal, US, Australia, Canada). 39% 
were P4P (individual outcome-based), and 29% were CED (collective outcome-based) 
agreements. The majority of CED endpoints were HEP (92%), such as overall survival, 
decrease in hospitalizations/ prescriptions, delay switch to insulin treatment, real 
world data collection (e.g. long term safety and efficacy, drug conditions of use in 
practice). In contrast, the majority of P4P were SEP (89%), such as assessment of short 
term effectiveness, targeting a short term laboratory value (e.g. decrease in total 
cholesterol levels, HbA1c, etc.). All oncology drugs P4P had SEP performance criteria. 
There were few P4P (14%) with HEP (e.g. fracture, graft rejection for transplant), and 
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objeCtives: Cost effectiveness analyses play a critical role in determining cov-
erage of novel drugs and devices. Increasingly, payers are demanding subgroup 
analyses to determine indications which would be covered by the national health 
system or insurance agency. Methods: To understand and review trends in the 
use of subgroup cost effectiveness analysis, we analyzed NICE HTAs for products 
approved between 2011-2012. Manufacturer submissions for CEA were compared 
to final review and decision by HTA agency. Analogs were identified and case 
studies were developed to further understand the use of subgroup analyses and 
cost effectiveness models. Results: Decisions made by NICE in 2011-2012 show 
increasing trends towards the use of subgroup analysis for determining indi-
cations for coverage by national payer bodies. Between 2011-2012, 80% of the 
assessments included subgroup analyses. Approximately half of them included 
cost effectiveness analyses for various subgroups. Interestingly, the ICER values 
estimated by NICE for the same subgroups showed a large variation (1X-3X fold 
difference) compared to ICER values estimated by manufacturers. Selected case 
studies highlighted that for several products, NICE is recommending treatments 
only for subgroups whose ICER values are within the cost effectiveness thresh-
old. ConClusions: New products need robust broader population and subgroup 
analyses for insurance coverage.
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objeCtives: To analyze the impact of changes in Brazil’s health care system leg-
islation from 2009 (CITEC) and after 2011 (CONITEC) on lawsuits for health tech-
nologies supply and federal spending. Methods: Survey of federal spending in 
health technologies supply through lawsuits. Results: Lawsuits with the federal 
government as a defendant for health technologies supply started in 2002. Ten years 
later there were 3,205 individual lawsuits for which the government spent US$ 
131.19 million. The number of lawsuits continued to grow, reaching 2,273 in 2008. 
Since 2009, the growth rate slowed, reaching the annual average of 1,579, showing 
a stabilizing trend over the last 3 years. Federal spending grew at an average rate of 
150% per year: 221% per year until 2008, decelerating to 60% per year since 2008. The 
impact of these lawsuits creates a cumulative effect in federal spending because 
the technologies provided are for chronic diseases and continuous use. In 2012 and 
2013, 5 medicines alone, all of them indicated for the treatment of rare diseases 
(e.g. idursulfase, galsulfase and eculizumab) represent more than 80% of the fed-
eral spending. ConClusions: Escalating lawsuits over the last decade in Brazil 
led to several initiatives that culminated with the publication of law 12,401/2011 
that created the National Committee for Health Technology Incorporation to assist 
the Ministry of Health in the incorporation of new technologies in Brazil’s health 
care system. The law established a deadline of 180 days for a decision to be made, 
based on scientific evidence of efficiency, accuracy, effectiveness and security, and 
on a comparative cost-benefit evaluation in relation to the technologies already 
incorporated. Decision must consider social participation, be clear and compre-
hensible. The deceleration in the annual rates of new lawsuits and the decrease in 
federal spending demonstrate that HTA applied to regulation may play a critical 
role in this context.
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objeCtives: In the last years HTA-Scientific-Advice (HTA-SA) has been assuming 
a relevant role in decision process for assessment of new technologies for pricing 
and reimbursement in Europe. Since the beginning of the SA-initiatives, AIFA has 
been involved in multi-dimensional and multi-national advices: parallel-SA with 
European Medicines Agency (EMA), European-Network of HTA (EUnetHTA) Early-
Dialogue, Tapestry Networks, National HTA-SA. The AIFA-HTA-SA procedure relates 
the assessment of manufacturer’s briefing book; consultancies with clinical and HTA 
experts; face-to-face meeting with manufacturer and final report. This study aims 
at presenting an analysis of the HTA-SA programs over the last 3 years. Methods: 
Comparative analysis of issues evaluated in different types of HTA-SA has been 
conducted, in terms of clinical development program (patients’characteristics and 
selection; choice of comparator; trial design; choice of endpoints, including patient-
reported-outcomes, stratification/subgroups; safety), cost-effectiveness (modeling, 
resource utilization, utility values) and Place in Therapy (value proposition, added 
benefit). Finally, an analysis of concordance between manufacturers proposal and 
AIFA-advice has been performed. Results: From 2011 to 2013, a total of 21 HTA-SAs 
were performed: 3 Tapestry-Networks-SAs; 3 National-HTA-SAs; 7 EUnetHTA-Early-
Dialogues; 8 parallel-EMA-HTA-SAs. Nervous system and cancer diseases were the 
main therapeutic areas of requests, accounting for 57% of total HTA-SAs (respec-
tively 6 products for each). The majority (52,4%) of HTA-SAs were requested in an 
early stage of clinical development (Phase I-II). The comparative analysis showed 
that clinical development items were systematically analysed among different types 
of HTA-SA, while the domains of cost-effectiveness and place in therapy were more 
relevant for EUnetHTA Early Dialogues and National HTA-SAs. The concordance 
analysis showed that target population, stratification/subgroups and choice of 
comparator(s) were critical issues. ConClusions: The HTA-SA-activities respond 
to the emerging need of early interaction among manufacturers, regulators and 
HTAs. Different types of HTA-SA reflect different institutional bodies approaches 
and peculiarities. The National-HTA-SA-program is expected to increase in the next 
future.
study was conducted among general public in Quetta, Pakistan by using a conveni-
ent sampling technique. A total of one thousand respondents were approached and 
927 consumers participated in the survey giving a response rate of 92.7%. Data was 
analyzed by using SPSS version 18.0 and descriptive statistics were reported where 
appropriate. Results: Majority of the respondents (n= 609, 65.7%) were not aware 
of possible side effects of their current medications. A total of 144 respondents 
(15.5%) believed that all medicines registered in Pakistan are safe to use and they 
do not have any side effects. About 44.4% (n= 412) of the respondents claimed that 
they share their unused medicines with family and friends who are having similar 
illness. Majority of respondents 87.7% (n= 813) were not satisfied with the drug 
information provided by the health care professionals. The present study also found 
that more than 80% of the respondents (n= 742) did report that they never read the 
labels of their medication before using. ConClusions: The present study revealed 
poor level of public knowledge regarding medication safety. It is evident that public 
underestimates the risk of their medications. There is a general lack of awareness 
and understanding among the public especially towards side effects.
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objeCtives: The aim of this analysis was to summarize the contribution of Colombian 
papers to ISPOR conferences from 1998 to 2013. Methods: It was developed a review 
of ISPOR Scientific Presentations Database from 1998 to 2013, filtering by abstract, 
by the word “Colombia” for each ISPOR meeting (International, European, Asian, and 
Latin American), we obtained a list of all abstracts those ones without Colombian 
authors were excluded. Abstracts were classified by disease, topic, and topic sub-
category taking into account the register of each one. It was taken into account if 
authors or abstract relate any support of pharmaceutical or/and devices industry. 
Descriptive statistics were applied by disease and study type. Results: A total of 258 
abstracts were identified, 25 were excluded because they have no Colombian authors; 
233 abstracts were included in the analysis, 111 from International (47.6%), 12 from 
European (5.2%), 1 from Asia-Pacific (0.4%) and 109 from Latin America Conference 
(46.8%). Over time, cumulative numbers of abstracts are increasing exponentially. The 
majority of abstracts were costs studies (76.4%), followed by Health Care Use & Policy 
Studies (13.3%), Clinical Outcomes Studies (6.0%), and others (10, 4.3%). The three 
most frequent diseases were cancer (12.4%), vaccine (12.0%) and infections (10.3%). 
The three most frequent cost studies developed were classified as cost-effectiveness 
analysis (61.8%), Cost of Illness studies (10.7%) and budget impact analysis (9.0%); 
Of included studies, 51.9% contain any author related with pharmaceutical or/and 
devices industry. There may be underreporting of studies due the filter was applied 
only for abstract content, neither by title nor authors; underreport on Scientific 
Presentations Database; and underreporting of pharmaceutical industries support 
due it is not disclosed on abstract. ConClusions: The contribution of Colombia to 
ISPOR Conferences have been increasing markedly, going from 1 paper presented in 
2004 to 93 papers presented in 2013
HealtH Care use & PoliCy studies – Health technology assessment Pro-
grams
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objeCtives: HTA activity is constantly growing over time at a global level, a trend 
observed in both countries with well-consolidated HTA agencies, such as the UK, 
as well as in HTA-emerging countries, such as Brazil. The objective of this study 
was to explore trends in HTA activity during 2012 and 2013 worldwide, along with 
flagging newcomers. Methods: Data were obtained from the Quintiles HTA Watch 
platform covering almost 100 HTA agencies in 32 countries. Published and ongo-
ing HTA are captured in the database on a regular basis. Entries published from 1st 
of January 2012 till 31stof December 2013 were selected. The number of published 
reports by each agency and country/region was counted and were also stratified 
by therapeutic area and indication. Data from selected agencies based on their 
impact on reimbursement decisions were further explored. Results: 3241 reports 
were found in total for all agencies monitored, out of which 1530 were published 
in 2012 and 1659 in 2013. HTA Activity in the UK is constantly rising as a total (214 
reports published in 2012 and 254 in 2013 from NICE, SMC and AWMSG), as well as 
in the individual agencies (NICE experimented a 28% increase in the number of 
published reports). Increasing trends were also observed in France, Sweden, Canada 
and Australia, while Germany and Spain remained rather stable. Cancer, diabetes, 
digestive and musculoskeletal indications were the object of more evaluations in 
2013 compared to 2012, while cardiovascular and central nervous systems indica-
tions experimented a decline in selected agencies. Newcomers include Colombia 
with IETS and more than 50 reports, and Spain with the Therapeutic Positioning 
Reports. ConClusions: Global statistics allowed us to describe trends in HTA activ-
ity that reinforce the conviction that evidence-based decisions are increasingly 
considered valuable/mandatory for reimbursement purposes and consequently, 
HTA activity is constantly in rise over the globe.
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